Bethany Sensenig
Director/Miembro de la Junta en SUPERNUS PHARMACEUTICALS, INC. .
Fortuna: - $ al 31/03/2024
Cargos activos de Bethany Sensenig
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SUPERNUS PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 21/08/2023 | - |
Independent Dir/Board Member | 21/08/2023 | - | |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Director Ejecutivo | - | - |
Director Financiero/CFO | - | - |
Historial de carrera de Bethany Sensenig
Antiguos cargos conocidos de Bethany Sensenig.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
9 METERS BIOPHARMA, INC. | Director Ejecutivo | 26/05/2023 | 17/07/2023 |
Director Financiero/CFO | 18/01/2022 | 17/07/2023 | |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Director Financiero/CFO | 01/03/2019 | 01/01/2022 |
BIOGEN INC. | Corporate Officer/Principal | 01/04/2006 | 01/03/2019 |
Formación de Bethany Sensenig.
Montreat College | Undergraduate Degree |
Western Carolina University | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 7 |
Israel | 2 |
Operativa
Director of Finance/CFO | 3 |
Chief Executive Officer | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
9 METERS BIOPHARMA, INC. | Health Technology |
BIOGEN INC. | Health Technology |
SUPERNUS PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Health Technology |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Health Services |
- Bolsa de valores
- Insiders
- Bethany Sensenig
- Experiencia